Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
Fadul CE, Thakur A, Kim J, Kassay-McAllister J, Schalk D, Lopes MB, Donahue J, Purow B, Dillon P, Le T, Schiff D, Liu Q, Lum LG. Fadul CE, et al. Among authors: schalk d. J Neurooncol. 2024 Jan;166(2):321-330. doi: 10.1007/s11060-024-04564-y. Epub 2024 Jan 23. J Neurooncol. 2024. PMID: 38263486 Free PMC article. Clinical Trial.
Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants.
Thakur A, Sorenson C, Norkina O, Schalk D, Ratanatharathorn V, Lum LG. Thakur A, et al. Among authors: schalk d. Transfusion. 2012 Jan;52(1):63-75. doi: 10.1111/j.1537-2995.2011.03232.x. Epub 2011 Jul 11. Transfusion. 2012. PMID: 21745212 Free PMC article.
CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L, Abidi MH, Pray C, Tomaszewski EN, Steele PA, Schalk DL, Yano H, Mitchell A, Dufresne M, Uberti JP, Ratanatharathorn V. Lum LG, et al. Biol Blood Marrow Transplant. 2013 Jun;19(6):925-33. doi: 10.1016/j.bbmt.2013.03.010. Epub 2013 Mar 22. Biol Blood Marrow Transplant. 2013. PMID: 23529012 Free PMC article. Clinical Trial.
Maspin expression in prostate tumor elicits host anti-tumor immunity.
Dzinic SH, Chen K, Thakur A, Kaplun A, Bonfil RD, Li X, Liu J, Bernardo MM, Saliganan A, Back JB, Yano H, Schalk DL, Tomaszewski EN, Beydoun AS, Dyson G, Mujagic A, Krass D, Dean I, Mi QS, Heath E, Sakr W, Lum LG, Sheng S. Dzinic SH, et al. Among authors: schalk dl. Oncotarget. 2014 Nov 30;5(22):11225-36. doi: 10.18632/oncotarget.2615. Oncotarget. 2014. PMID: 25373490 Free PMC article.
Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.
Lum LG, Thakur A, Kondadasula SV, Al-Kadhimi Z, Deol A, Tomaszewski EN, Yano H, Schalk DL, Ayash L, Zonder JA, Uberti JP, Abidi MH, Ratanatharathorn V. Lum LG, et al. Biol Blood Marrow Transplant. 2016 May;22(5):869-78. doi: 10.1016/j.bbmt.2015.12.030. Epub 2016 Jan 28. Biol Blood Marrow Transplant. 2016. PMID: 26827660 Free PMC article. Clinical Trial.
44 results